A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

NCT04056117 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

596

Enrollment

INDUSTRY

Sponsor class

Conditions

Shigellosis

Interventions

BIOLOGICAL: Shigella 4V
BIOLOGICAL: MenACWY
BIOLOGICAL: Rabies
BIOLOGICAL: Diphtheria, Tetanus and Pertussis (DTaP)
BIOLOGICAL: Placebo

Sponsor

LimmaTech Biologics AG

Collaborators

[object Object]
[object Object]